XiAn International Medical Investment Co Ltd
XiAn International Medical Investment Co Ltd operates in the health care providers and services sector, generating revenue through medical investment activities.
Business. XiAn International Medical Investment Co Ltd operates in the health care providers and services sector, generating revenue through medical investment activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
XiAn International Medical Investment Co Ltd operates in the health care providers and services sector, generating revenue through medical investment activities.
The company maintains a capital structure characterized by significant leverage, with long-term debt of CNY 4.29 billion against total equity of CNY 3.32 billion, resulting in a debt-to-equity ratio of 1.29. Liquidity is constrained, evidenced by a current ratio of 0.25, which indicates that current liabilities significantly exceed current assets. Despite negative net income of CNY -313.1 million, the firm generated positive operating cash flow of CNY 1.28 billion, though free cash flow remained negative at CNY -145.7 million due to capital expenditures of CNY 262.5 million.
Profitability metrics reflect ongoing losses, with a return on equity of -7.7% and return on assets of -2.63%. The company reported an operating income of CNY -400.7 million on revenues of CNY 4.07 billion, indicating a gross profit margin of approximately 8.2% and significant operating leverage challenges. Without cohort median data for direct comparison, the negative returns suggest the company is in a growth or turnaround phase where profitability has not yet been achieved.
- High leverage with a debt-to-equity ratio of 1.29 and negative net cash position.
- Strong operating cash flow of CNY 1.28 billion offsets negative free cash flow of CNY -145.7 million.
- Profitability is negative with ROE of -7.7% and operating income of CNY -400.7 million.
- Liquidity is tight with a current ratio of 0.25, indicating potential short-term funding pressures.
- Low dilution risk with stable share count of 2.24 billion shares.
Bull / Bear case
Generated · model-assistedRevenue grew 8.7% annually over four years, demonstrating consistent top-line expansion despite ongoing profitability challenges.
Free cash flow improved significantly with a 60.3% year-over-year increase, indicating better cash generation efficiency.
Net losses narrowed substantially from 2023 to 2025, showing a clear trend toward improved operational profitability.
Gross profit turned positive in 2024 and 2025, suggesting core business operations are generating value before operating expenses.
Long-term debt decreased slightly in the most recent period, reflecting modest progress in balance sheet deleveraging efforts.
The company faces high credit risk, signaling significant concerns regarding its ability to meet financial obligations.
Net margin and ROE remain negative, placing the company in the bottom quartile compared to peer cohorts.
Debt-to-equity ratio of 1.29 is significantly higher than the cohort median of 0.4, indicating excessive leverage.
Cash conversion is severely negative at -3.95, far worse than the cohort median of 1.2.
In focus — financials by report
Revenue ¥4.82B, +4,3% YoY; Operating income +25,5% YoY.
- ▍Revenue ¥4.82B, +4,3% YoY
- ▍Operating income +25,5% YoY
- ▍Net income +31,0% YoY
- ▍Free cash flow +50,9% YoY
- ▍Net margin -5.3%
Revenue ¥4.62B, +70,3% YoY; Operating income +59,2% YoY.
- ▍Revenue ¥4.62B, +70,3% YoY
- ▍Operating income +59,2% YoY
- ▍Net income +68,7% YoY
- ▍Free cash flow +62,7% YoY
- ▍Net margin -8.0%
Revenue ¥2.71B, −7,2% YoY; Operating income −25,1% YoY.
- ▍Revenue ¥2.71B, −7,2% YoY
- ▍Operating income −25,1% YoY
- ▍Net income −43,1% YoY
- ▍Free cash flow +7,4% YoY
- ▍Net margin -43.4%
Revenue ¥2.92B; Operating income -¥908.0M.
- ▍Revenue ¥2.92B
- ▍Operating income -¥908.0M
- ▍Net margin -28.1%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Enterprise Valuemarket_cap - net_cash
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Capmarket_price * shares_outstanding_diluted
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- XiAn International Medical Investment Co Ltd Market data — financials · 2026-07-06
Ownership & reference
Leadership
- Ruixuan LiuPresident, Director